244 reports of this reaction
2.4% of all ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE reports
#6 most reported adverse reaction
INSOMNIA is the #6 most commonly reported adverse reaction for ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 244 FDA adverse event reports linking ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE to INSOMNIA. This represents approximately 2.4% of all 10,191 adverse event reports for this drug.
Patients taking ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 244 FDA reports for ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 2.4% of all adverse event reports for ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience insomnia while taking ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.